New drug combo offers hope for kids with Tough-to-Treat leukemia
NCT ID NCT05192889
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 32 times
Summary
This study tests a combination of two drugs, venetoclax and navitoclax, in children whose acute lymphoblastic leukemia has returned or not responded to standard therapy. The goal is to see if this combination can clear the cancer from the bone marrow (called minimal residual disease negativity). About 35 children will take part, and the study also looks at adding other drugs like blinatumomab or high-dose cytarabine depending on the child's cancer type.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
Conditions
Explore the condition pages connected to this study.